As of 2026-01-07, the Intrinsic Value of Johnson & Johnson (JNJ) is 196.31 USD. This JNJ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 204.79 USD, the upside of Johnson & Johnson is -4.10%.
The range of the Intrinsic Value is 126.94 - 424.28 USD
Based on its market price of 204.79 USD and our intrinsic valuation, Johnson & Johnson (JNJ) is overvalued by 4.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 126.94 - 424.28 | 196.31 | -4.1% |
| DCF (Growth 10y) | 148.46 - 455.75 | 220.62 | 7.7% |
| DCF (EBITDA 5y) | 78.13 - 96.82 | 86.62 | -57.7% |
| DCF (EBITDA 10y) | 103.67 - 131.49 | 116.26 | -43.2% |
| Fair Value | 127.40 - 127.40 | 127.40 | -37.79% |
| P/E | 130.23 - 259.60 | 176.20 | -14.0% |
| EV/EBITDA | 81.70 - 134.42 | 101.20 | -50.6% |
| EPV | 97.00 - 132.04 | 114.52 | -44.1% |
| DDM - Stable | 126.59 - 505.38 | 315.98 | 54.3% |
| DDM - Multi | 122.44 - 361.55 | 180.77 | -11.7% |
| Market Cap (mil) | 493,400.56 |
| Beta | 0.18 |
| Outstanding shares (mil) | 2,409.30 |
| Enterprise Value (mil) | 530,800.56 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.31% |
| Cost of Debt | 6.33% |
| WACC | 7.19% |